The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Biologics Fill / Finish Services Market, 2019 - 2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    May 2019

  • Pages
    483

  • View Count
    8561

Example Insights

GMP - Context GMP - Primary Research GMP - Market Overview
GMP - Service Providers GMP - Packaging Form GMP - Recent Expansions
GMP - Partnerships and Collaborations GMP Competitve Analysis GMP - Capacity Analysis
GMP - Demand and Supply Analysis GMP - Market Forecast GMP - Market Forecast

Overview

In order to meet the anticipated future demand for biologics fill / finish services in the American and European markets, contract service providers based in these regions have made significant investments in accruing additional capacity for drug product manufacturing and fill / finish

-- Chief Commercial Officer, large-sized company

Biologics constitute a majority of the top selling drugs and presently represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, since the launch of recombinant protein-based therapies around three decades earlier, the overall biologics market has grown at an annualized rate of over 12%. It is also worth highlighting that more than 5,000 biopharmaceutical product candidates are currently under development.  Despite the fact that biopharmaceuticals offer significant profit margins, the sponsors of such pharmacological interventions are plagued by high costs of development and complex production protocols. As a result, several start-ups / small-sized companies and certain pharma giants have begun outsourcing different aspects of their business operations to contract service providers. According to the 2017 Nice Insight CDMO survey, about 54% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development projects.  Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are known to offer significant benefits, such as reduction in capital investment, access to larger production capacities, reductions in time-to-market and reduced commercialization risk. 

Specifically, fill / finish is the final step in the production process and is considered among the most crucial stages of drug product manufacturing. Biologics drug products require special procedures and equipment for fill / finish operations in order to ensure product integrity and safety. As this operation is heavily outsourced, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill / finish technologies. Pharmaceutical drug manufacturers have not hesitated to collaborate with contract service providers to leverage the latter’s experience and expertise in the latest fill / finish technologies. Currently, over 115 companies are actively providing fill / finish services for biologics. In the recent past, many service providers have also forged alliances / acquired other players in order to enhance their service offerings. Given the ongoing COVID-19 pandemic, we expect several contract service providers to expand their fill / finish capacity in the near future to meet the high demand for filling / finishing various vaccine products that are currently under development.

Scope of the Report

The ‘Biologics Fill / Finish Service Providers, 2019-2030’ report features an extensive study on the contract service providers offering drug product manufacturing services within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of companies that claim to specialize in fill / finish operations. Amongst other elements, the report includes: 

  • A detailed review of the overall landscape of contract fill / finish services market for biopharmaceuticals, featuring a list of active service providers and detailed analysis based on a number of relevant parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics filled (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, viral products, oligonucleotides and others), year of establishment, company size and geographical location of the service provider, count and location of affiliated fill / finish facilities, number of additional services offered (lyophilization, labelling, quality testing, storage and distribution services), dosage forms handled (liquid and lyophilized), and types of primary packaging containers handled (ampoules, cartridges, syringes and vials),  including details on fill / finish capacity and fill volume range.

  • A region-wise, company competitiveness analysis, highlighting prominent fill / finish service providers across various packaging types, based on supplier strength (considering experience and company size of the service provider), service strength (considering number of fill / finish facilities, number of continents where the aforementioned facilities are located, number of additional services offered and scale of operation) and types of biologics handled.     
  • Elaborate profiles of key players across key geographies (North America, Europe and Asia-Pacific), which were shortlisted based on our proprietary company competitiveness analysis. Each profile provides an overview of the company, information on its overall service portfolio, fill / finish facilities, financial performance (if available), and details on partnerships, expansions and recent awards and accolades, as well as an informed future outlook. 
  • An analysis of the recent collaborations (signed since 2013) focused on the contract fill / finish services for biologics, based on various parameters, such as year of agreement, type of agreement, scale of operation of the project, focus area, types of services mentioned in the deal, types of biologics involved and location of facility where the project is to be executed. 
  • A detailed analysis of the expansions undertaken (since 2013) by various service providers for augmenting their respective fill / finish service portfolios, based on a number of parameters, including year of expansion, type of expansion (capacity expansion and new facility), geographical location of facility, type of packaging container involved, scale of operation (as mentioned in the expansion terms), types of services and biologics involved, expansion details (in terms of new area added to existing facilities, if available) and most active players (in terms of number of instances).
  • An estimate of the global, contract fill / finish capacity, by taking into consideration the capacities of various fill / finish service providers (as available on respective company websites), collected via secondary and primary research. The study examines the distribution of number of packaging units and volume of biologics filled, across various types of packaging containers (ampoules, cartridges, syringes, and vials), based on the size of the company / organization (small-sized, mid-sized and large)  and geography (North America, Europe and Asia Pacific).
  • An informed estimate of the annual demand for fill / finish of biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of the abovementioned products. 
  • An analysis to identify the key performance indicators for service providers active in the domain, based on information gathered via secondary research (for top-ten pharmaceutical players) and primary research.
  • A case study to highlight the benefits of using robotic / automated equipment for aseptic fill / finish processes; the study provides a list of equipment manufacturers providing robots suitable for pharmaceutical operations.
  • A case study to highlight the role of ready-to-use packaging containers in aseptic fill / finish operations; the study provides a list of suppliers providing the ready-to-use components.
  • A discussion on the potential growth areas, such as growing biopharmaceutical pipeline, increasing outsourcing of fill / finish operations, rising focus on self-administration enabling drug delivery devices and growing opportunities in Asia-Pacific region, which are likely to present in the coming years.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs, and outsourcing trends related to fill / finish operations, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] types of primary packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] types of biologics (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, viral products, oligonucleotides and others), [C] company size (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial), [E] key therapeutic areas (cancer, infectious diseases, autoimmune diseases, cardiovascular diseases and other indications), and [F] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia-Pacific (Japan, China, South Korea, India and Australia)). To account for the uncertainties associated with the fill / finish of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Ales Sima, Business Development Manager, oncomed manufacturing 
  • Gregor Kawaletz, Chief Commercial Officer, IDT Biologika
  • Jos Vergeest, International Business Developer, HALIX
  • Purushottam Singnurkar, Research Director and Head of Formulation Development, Syngene International

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the biopharmaceutical fill / finish contract services market in the mid to long term.

Chapter 3 provides a general introduction to biopharmaceuticals and contract manufacturing. The chapter features a detailed discussion on the need for outsourcing within the biopharmaceutical industry and highlights the key operations outsourced by the pharmaceutical players, including fill / finish. It includes an overview of the fill / finish operations, along with information on key factors that need to be considered during the selection of fill / finish service providers, as well as the advantages and disadvantages associated by outsourcing fill / finish operations .

Chapter 4 provides an overview of the overall biopharmaceutical fill / finish contract services landscape. It includes information related to over 115 contract service providers that are currently active in this domain. It features in-depth analyses of the market, based on a number of relevant parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics filled (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, viral products, oligonucleotides and others), year of establishment, company size and geographical location of the service providers, location of fill / finish facilities, number of additional services (lyophilization, labelling, quality testing, storage and distribution services), dosage forms handled (liquid and lyophilized), information on various types of primary packaging containers (ampoules, cartridges, syringes and vials), highlighting details on the fill / finish capacity and fill volume range. 

Chapter 5 features a comprehensive company competitiveness analysis of service providers based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of the type of packaging used for fill / finish services, supplier strength (considering experience and company size of service provider), service strength (considering number of fill / finish facilities, number of continents where aforementioned facilities are based,  number of additional services and highest scale of operation)  and type of biologics.

Chapter 6 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in North America. Each profile presents a brief overview of the company, its overall contract service offerings highlighting the capabilities of drug product facilities (if available), financial information (if available), recent developments comprising of partnerships, expansions and, awards and accolades, and a section on future outlook. 

Chapter 7 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Europe. Each profile presents a brief overview of the company, its overall contract service offerings highlighting the capabilities of drug product facilities (if available), financial information (if available), recent developments comprising of partnerships, expansions and, awards and accolades and a section on future outlook.  

Chapter 8 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the Asia-Pacific region. Each profile presents a brief overview of the company, its overall contract service offerings highlighting the capabilities of drug product facilities (if available), financial information (if available), recent developments comprising of partnerships, expansions and, awards and accolades and a section on future outlook.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2013. It includes a brief description of the purpose of the partnership models (including acquisition, supply agreement, service alliance, merger and joint venture) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of agreement, the scale of operation of the project, focus area, types services provided, types of biologics and location of the facilities where the project is to be executed. 

Chapter 10 presents detailed analyses of the recent fill / finish specific expansions that have taken place since 2013. It comprises of expansions for increasing existing capabilities as well as setting-up of new facilities by the service providers. These have been analyzed on various parameters, including year of expansion, type of expansion, geographical location of the facility, type of packaging container involved, scale of operation (as mentioned in the expansion terms), types of services, type of biologics involved, expansion details (in terms of new area added to the existing facilities) and also highlights the most active players (in terms of number of instances) in the domain.

Chapter 11 features a comprehensive analysis of the global fill / finish capacity, by taking into consideration the container processing capacities of various fill / finish service providers (as available on respective company websites). The study examines the distribution of global biopharmaceutical fill / finish capacity of the industry in terms of number of packaging units, type of packaging container (ampoules, cartridges, syringes and vials), size of the player (small-sized, mid-sized and large) and geography (North America, Europe and Asia-Pacific).

Chapter 12 features a comprehensive analysis of the annual demand for fill / finish of biologics  (in number of units) by type of packaging container, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of the abovementioned products. 

Chapter 13 features an analysis on the key performance indicators of service providers based on information available for top-ten biopharmaceutical players on various public platforms, as well as inputs from primary research.
 
Chapter 14 highlights the potential growth drivers for contract service providers offering fill / finish services in the biopharmaceutical market. It highlights the various opportunities associated with the growing biopharmaceutical pipeline, increase in outsourcing of fill / finish operations, rising focus on self-administration of drugs / therapies and opportunities in the Asia-Pacific region.

Chapter 15 presents a comprehensive market forecast analysis, highlighting the likely growth of the biologics’ fill / finish services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] types of primary packaging containers used for fill / finish (ampoules, cartridges, syringes and vials), [B] types of biologics filled (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, viral products, oligonucleotides and others), [C] company size (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial), [E] key therapeutic areas (cancer, infectious diseases, autoimmune diseases, cardiovascular diseases and other indications, and [F] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and rest of the Europe), Asia (Japan, China, South Korea and India).

Chapter 16 is a case study focused on use of robotic systems in fill / finish operations. It provides a list of equipment used by the service providers (wherever specified) for fill / finish, highlighting the role of robotics in various manufacturing operations. It also includes list of companies providing robots for use in pharmaceutical production processes.  

Chapter 17 is a case study which describes the use of ready-to-use packaging components in the aseptic fill / finish operations. It also provides a list of suppliers providing ready-to-use components.

Chapter 18 is a summary of the entire report. It provides the key takeaways and presents our independent opinion on the biopharmaceutical fill /finish contract services market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of biopharmaceutical fill / finish service providers.

Chapter 19 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical fill / finish contract manufacturing domain. In this study, we spoke to Ales Sima (Business Development Manager, oncomed manufacturing), Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Jos Vergeest (International Business Developer, HALIX) and Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International).

Chapter 20 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 21 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Biologics
3.3. Need for Outsourcing Biologics-related Operations
3.4. Introduction to Contract Manufacturing
3.5. Commonly Outsourced Operations in the Biopharmaceutical Industry
3.5.1. Biologics Fill / Finish Operations
3.6. Basic Guidelines for Selecting a Fill / Finish Service Provider
3.7. Advantages of Outsourcing Fill / Finish Services
3.8. Risks and Challenges of Outsourcing Fill / Finish Operations

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Biologics Fill / Finish Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Fill / Finish Facilities
4.2.5. Analysis by Type of Packaging
4.2.6. Analysis by Additional Services Offered
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Type of Biologics Filled

5. COMPANY COMPETITVE ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Input Parameters

5.4. Competitiveness Analysis: Biologics Fill / Finish Service Providers in North America
5.4.1. Companies Offering Fill / Finish Services for Ampoules
5.4.2. Companies Offering Fill / Finish Services for Cartridges
5.4.3. Companies Offering Fill / Finish Services for Syringes
5.4.4. Companies Offering Fill / Finish Services for Vials

5.5. Competitiveness Analysis: Fill / Finish Service Providers in Europe
5.5.1. Companies Offering Fill / Finish Services for Ampoules
5.5.2. Companies Offering Fill / Finish Services for Cartridges
5.5.3. Companies Offering Fill / Finish Services for Syringes
5.5.4. Companies Offering Fill / Finish Services for Vials

5.6. Competitiveness Analysis: Fill / Finish Service Providers of Asia-Pacific
5.6.1. Companies Offering Fill / Finish Services for Ampoules
5.6.2. Companies Offering Fill / Finish Services for Cartridges
5.6.3. Companies Offering Fill / Finish Services for Syringes
5.6.4. Companies Offering Fill / Finish Services for Vials

6. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. Advanced BioScience Laboratories (ABL)
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Recent Developments
6.2.4. Future Outlook

6.3. Albany Molecular Research (AMRI)
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Financial Information
6.3.4. Recent Developments
6.3.5. Future Outlook

6.4. BioPharma Solutions
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Financial Information
6.4.4. Recent Developments
6.4.5. Future Outlook

6.5. BioReliance
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Financial Information
6.5.4. Recent Developments
6.5.5. Future Outlook

6.6. Emergent BioSolutions
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Financial Information
6.6.4. Recent Developments
6.6.5. Future Outlook

6.7. Patheon
6.7.1. Company Overview
6.7.2. Services Portfolio
6.7.3. Financial Information
6.7.4. Recent Developments
6.7.5. Future Outlook

7. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN EUROPE: COMPANY PROFILES
7.1. Chapter Overview
7.2. Boehringer Ingelheim BioXcellence
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Financial Information
7.2.4. Recent Developments
7.2.5. Future Outlook

7.3. IDT Biologika
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3. Recent Developments
7.3.4. Future Outlook

7.4. Lonza
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Financial Information
7.4.4. Recent Developments
7.4.5. Future Outlook

7.5. Recipharm
7.5.1. Company Overview
7.5.2. Service Portfolio
7.5.3. Financial Information
7.5.3. Recent Developments
7.5.4. Future Outlook

7.6. Vetter Pharma
7.6.1. Company Overview
7.6.2. Service Portfolio
7.6.3. Recent Developments
7.6.4. Future Outlook

8. BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC: COMPANY PROFILES
8.1. Chapter Overview
8.2. Biocon
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Financial Information
8.2.4. Recent Developments
8.2.5. Future Outlook

8.3. ChemPartner
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Recent Developments
8.3.4. Future Outlook

8.4. LuinaBio
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Recent Developments
8.4.4. Future Outlook

8.5. Mycenax Biotech
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Financial Information
8.5.3. Recent Developments
8.5.4. Future Outlook

8.6. Wuxi Biologics
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Financial Information
8.6.4. Recent Developments
8.6.4. Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Biologics Fill / Finish Service Providers: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Service
9.3.4. Analysis by Scale of Operation
9.3.5. Analysis by Type of Biologic
9.3.6. Analysis by Geographical Location
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Service Alliances and Supply Agreements: Analysis by Type of Service
9.3.9. Acquisitions and Mergers: Analysis by Type of Servic

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Biologics Fill / Finish Service Providers: Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Packaging
10.2.4. Analysis by Type of Service
10.2.5. Analysis by Type of Biologic
10.2.6. Analysis by Type of Biologic and Scale of Operation
10.2.7. Analysis by Geographical Location
10.2.8. Most Active Players: Analysis by Type of Service and Type of Biologic
10.2.9. Expansions in North America: Analysis by Type of Service and Type of Biologic
10.2.10. Expansions in Europe: Analysis by Type of Service and Type of Biologic
10.2.11. Expansions in Asia-Pacific: Analysis by Type of Service and Type of Biologic

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Global Biologics Fill / Finish Capacity (by Number of Units)
11.3.1. Analysis by Type of Packaging
11.3.2. Analysis by Size of Manufacturer
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Fill / Finish Facilities

11.4. Global Biologics Fill / Finish Capacity (by Volume)
11.4.1. Analysis by Type of Packaging
11.4.2. Analysis by Size of Manufacturer
11.4.3. Analysis by Scale of Operation
11.4.4. Analysis by Location of Headquarters
11.4.5. Analysis by Location of Fill / Finish Facilities

11.5. Global Biologics Fill / Finish Capacity: Ampoules (by Number of Units)
11.5.1 Analysis by Size of Manufacturer
11.5.2 Analysis by Scale of Operation
11.5.3. Analysis by Location of Headquarters
11.5.4 Analysis by Location of Fill / Finish Facilities

11.6. Global Biologics Fill / Finish Capacity: Ampoules (by Volume)
11.6.1. Analysis by Size of Manufacturer
11.6.2. Analysis by Scale of Operation
11.6.3. Analysis by Location of Headquarters
11.6.4. Analysis by Location of Fill / Finish Facilities

11.7. Global Biologics Fill / Finish Capacity: Cartridges (by Number of Units)
11.7.1. Analysis by Size of Manufacturer
11.7.2. Analysis by Scale of Operation
11.7.3. Analysis by Location of Headquarters
11.7.4. Analysis by Location of Fill / Finish Facilities

11.8. Global Biologics Fill / Finish Capacity: Cartridges (by Volume)
11.8.1. Analysis by Size of Manufacturer
11.8.2. Analysis by Scale of Operation
11.8.3. Analysis by Location of Headquarters
11.8.4. Analysis by Location of Fill / Finish Facilities

11.9. Global Biologics Fill / Finish Capacity: Syringes (by Number of Units)
11.9.1 Analysis by Size of Manufacturer
11.9.2 Analysis by Scale of Operation
11.9.3. Analysis by Location of Headquarters
11.9.4 Analysis by Location of Fill / Finish Facilities

11.10. Global Biologics Fill / Finish Capacity: Syringes (by Volume)
11.10.1. Analysis by Size of Manufacturer
11.10.2. Analysis by Scale of Operation
11.10.3. Analysis by Location of Headquarters
11.10.4. Analysis by Location of Fill / Finish Facilities

11.11. Global Biologics Fill / Finish Capacity: Vials (by Number of Units)
11.11.1 Analysis by Size of Manufacturer
11.11.2 Analysis by Scale of Operation
11.11.3. Analysis by Location of Headquarters
11.11.4. Analysis by Location of Fill / Finish Facilities

11.12. Global Biologics Fill / Finish Capacity: Vials (by Volume)
11.12.1. Analysis by Size of Manufacturer
11.12.2. Analysis by Scale of Operation
11.12.3. Analysis by Location of Headquarters
11.12.4. Analysis by Location of Fill / Finish Facilities

11.13. Conclusion

12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Assumptions and Methodology
12.3. Global Demand for Biologics Fill / Finish Services
12.3.1. Analysis by Type of Packaging
12.3.2. Analysis by Scale of Operation
12.3.3. Analysis by Type of Biologic
12.3.4. Analysis by Therapeutic Area
12.3.5. Analysis by Geographical Location
12.4. Demand and Supply Analysis

13. BIOLOGICS MANUFACTURING AND FILL / FINISH: KEY PERFORMANCE INDICATOR ANALYSIS
13.1. Chapter Overview
13.2. Biologics Manufacturing and Fill / Finish: KPI Definitions
13.2.1. Financial Indicators
13.2.1.1. Most Important KPIs
13.2.1.2. Industry Perspective
13.2.1.2.1. Big Pharma Perspective 
13.2.1.2.2. Contract Manufacturers’ Perspective 

13.2.2. Process / Capability Indicators
13.2.2.1. Most Important KPIs
13.2.2.2. Industry Perspective
13.2.2.2.1. Big Pharma Perspective 
13.2.2.2.2. Contract Manufacturers’ Perspective 

13.2.3. Market Reputation Indicators
13.2.3.1. Most Important KPIs
13.2.3.2. Industry Perspective
13.2.3.2.1. Big Pharma Perspective 
13.2.3.2.2. Contract Manufacturers’ Perspective 

13.2.4. Other Important Performance Indicators
13.3.5. Conclusion

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Overall Biologics Contract Manufacturing Market, 2019-2030
14.4. Overall Biologics Fill / Finish Services Market, 2019-2030
14.4.1. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Packaging
14.4.2. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Scale of Operation
14.4.3. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Biologic
14.4.4. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Therapeutic Area
14.4.5. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Geographical Region
14.4.5.1. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Packaging
14.4.5.2. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Scale of Operation
14.4.5.3. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Biologic
14.4.5.4. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Therapeutic Area
14.4.5.5. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Packaging
14.4.5.6. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Scale of Operation
14.4.5.7. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Biologic
14.4.5.8. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Therapeutic Area
14.4.5.9. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Packaging
14.4.5.10. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Scale of Operation
14.4.5.11. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Biologic
14.4.5.12. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

14.5. Biologics Fill / Finish Services Market for Ampoules, 2019-2030
14.5.2. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Scale of Operation
14.5.2. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Type of Biologic
14.5.3. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Therapeutic Area
14.5.4. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Geographical Region
14.5.4.1. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Scale of Operation
14.5.4.2. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Type of Biologic
14.5.4.3. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Therapeutic Area
14.5.4.4. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Scale of Operation
14.5.4.5. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Type of Biologic
14.5.4.6. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Therapeutic Area
14.5.4.7. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Scale of Operation
14.5.4.8. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Type of Biologic
14.5.4.9. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

14.6. Biologics Fill / Finish Services Market for Cartridges, 2019-2030
14.6.1. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Scale of Operation
14.6.2. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Type of Biologic
14.6.3. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Therapeutic Area
14.6.4. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Geographical Region
14.6.4.1. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Scale of Operation
14.6.4.2. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Type of Biologic
14.6.4.3. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Therapeutic Area
14.6.4.4. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Scale of Operation
14.6.4.5. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Type of Biologic
14.6.4.6. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Therapeutic Area
14.6.4.7. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Scale of Operation
14.6.4.8. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Type of Biologic
14.6.4.9. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

14.7. Biologics Fill / Finish Services Market for Syringes, 2019-2030
14.7.1. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Scale of Operation
14.7.2. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Type of Biologic
14.7.3. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Therapeutic Area
14.7.4. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Geographical Region
14.7.4.1. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Scale of Operation
14.7.4.2. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Type of Biologic
14.7.4.3. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Therapeutic Area
14.7.4.4. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Scale of Operation
14.7.4.5. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Type of Biologic
14.7.4.6. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Therapeutic Area
14.7.4.7. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Scale of Operation
14.7.4.8. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Type of Biologic
14.7.4.9. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

14.8. Biologics Fill / Finish Services Market for Vials, 2019-2030
14.8.1. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Scale of Operation
14.8.2. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Type of Biologic
14.8.3. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Therapeutic Area
14.8.4. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Geographical Region
14.8.4.1. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Scale of Operation
14.8.4.2. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Type of Biologic
14.8.4.3. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Therapeutic Area
14.8.4.4. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Scale of Operation
14.8.4.5. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Type of Biologic
14.8.4.6. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Therapeutic Area
14.8.4.7. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Scale of Operation
14.8.4.8. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Type of Biologic
14.8.4.9. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Therapeutic Area

15. FUTURE GROWTH OPPORTUNITIES
15.1. Chapter Overview
15.2. Growing Biopharmaceutical Pipeline
15.3. Increase in Outsourcing Fill / Finish Activities
15.4. Rising Focus on Self-Administration
15.5. Advances in Aseptic Fill / Finish Technologies
15.6. Growing Opportunities in the Asia-Pacific Region

16. CASE STUDY: ROBOTIC SYSTEMS IN FILL / FINISH OPERATIONS
16.1. Chapter Overview
16.2. Contract Service Providers: List of Fill / Finish Equipment
16.3. Role of Robotic Systems in Fill / Finish Operations
16.3.1. Types of Robots Used in Pharmaceutical Operations
16.3.2. Key Considerations for Selecting a Robotic System
16.3.3. Advantages of Robotic Systems
16.3.4. Disadvantages of Robotic Systems
16.4. Companies Providing Robots for Use in the Pharmaceutical Industry
16.5. Concluding Remarks

17. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS IN ASEPTIC FILL / FINISH OPERATIONS
17.1. Chapter Overview
17.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
17.2.1. Advantages of Ready-to-Use Packaging Components
17.2.2. Disadvantages of Ready-to-Use Packaging Components
17.3. Companies Providing Ready-to-Use Packaging Components
17.4. Concluding Remarks

18. CONCLUSION
18.1. Outsourcing of Drug Product Filling and Packaging Operations is Driven by the Growing Pipeline of Biologics and Biosimilars
18.2. The Contract Fill / Finish Services Landscape Features a Mix of Large and Mid-sized Players, Offering a Variety of Services for End-Stage Product Development
18.3 North America and Europe have Emerged as Key Hubs for Fill / Finish Services
18.4 Many Players have Entered into Strategic Collaborations and are Actively Expanding and Upgrading Their Existing Infrastructure to Enhance their Service Offerings and Drug Product Development Capabilities
18.5 To Cater to the Growing Demand for Fill / Finish Services, Many Players are Entering into Strategic Partnerships and Expanding / Upgrading Existing Infrastructure
18.6 As the Annual Demand for Fill / Finish of Biologics is Likely to Increase in Future, Service Providers will be Required to Invest in Additional Capacity
18.7 Given Existing Trends in Outsourcing Fill / Finish Operations, the Market is Anticipated to Witness Significant Growth in the Coming Decade

19. INTERVIEW TRANSCRIPTS
19.1 Chapter Overview
19.2 HALIX
19.2.1 Interview Transcript: Jos Vergeest, International Business Developer
19.3 IDT Biologika
19.3.1. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer
19.4 oncomed manufacturing
19.4.1 Interview Transcript: Ales Sima, Business Development Manager
19.5. Syngene
19.5.1 Interview Transcript: Purushottam Singnurkar, Research Director and Head of Formulation Development

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Types of Biologics
Figure 3.2. Types of Third-Party Service Providers
Figure 3.3. Commonly Outsourced Operations
Figure 3.4. Steps Involved in Fill / Finish of Biologics
Figure 3.5. Key Considerations for Selecting a CMO Partner
Figure 3.6. Risks and Challenges Associated with Outsourcing Biologics Fill / Finish Operations
Figure 4.1. Biologics Fill / Finish Service Providers: Analysis by Year of Establishment
Figure 4.2. Biologics Fill / Finish Service Providers: Analysis by Company Size
Figure 4.3. Biologics Fill / Finish Service Providers: Analysis by Location of Headquarters
Figure 4.4. Biologics Fill / Finish Service Providers: Analysis by Location of Fill / Finish Facilities
Figure 4.5. Biologics Fill / Finish Service Providers: Analysis by Type of Packaging
Figure 4.6. Biologics Fill / Finish Service Providers: Analysis by Additional Services Offered
Figure 4.7. Biologics Fill / Finish Service Providers: Analysis by Scale of Operation
Figure 4.8. Biologics Fill / Finish Service Providers: Analysis by Type of Biologic
Figure 5.1. Competitiveness Analysis of Biologics Fill / Finish Service Providers in North America
Figure 5.2. Competitiveness Analysis of North American Companies Offering Fill / Finish Services for Ampoules
Figure 5.3. Competitiveness Analysis of North American Companies Offering Fill / Finish Services for Cartridges
Figure 5.4. Competitiveness Analysis of North American Companies Offering Fill / Finish Services for Syringes
Figure 5.5. Competitiveness Analysis of North American Companies Offering Fill / Finish Services for Vials
Figure 5.6. Competitiveness Analysis of Biologics Fill / Finish Service Providers in Europe
Figure 5.7. Competitiveness Analysis of European Service Providers Offering Fill / Finish for Ampoules
Figure 5.8. Competitiveness Analysis of European Service Providers Offering Fill / Finish for Cartridges
Figure 5.9. Competitiveness Analysis European Service Providers Offering Fill / Finish for Syringes
Figure 5.10. Competitiveness Analysis of European Service Providers Offering Fill / Finish for Vials
Figure 5.11. Competitiveness Analysis of Biologics Fill / Finish Service Providers in Asia-Pacific
Figure 5.12. Competitiveness Analysis of Asia-Pacific Service Providers Offering Fill / Finish for Ampoules
Figure 5.13. Competitiveness Analysis of Asia-Pacific Service Providers Offering Fill / Finish for Cartridges
Figure 5.14. Competitiveness Analysis of Asia-Pacific Service Providers Offering Fill / Finish for Syringes
Figure 5.15. Competitiveness Analysis of Asia-Pacific Service Providers Offering Fill / Finish for Vials
Figure 6.1. ABL: Overview of Service Portfolio
Figure 6.2. AMRI: Overview of Service Portfolio
Figure 6.3. AMRI: Annual Revenues, 2012- Q1 2017 (USD Million)
Figure 6.4. AMRI: Revenues by Business Divisions, 2016 (USD Million)
Figure 6.5. BioPharma Solutions: Overview of Service Portfolio
Figure 6.6. Baxter International: Annual Revenues, 2012 –2018 (USD Billion)
Figure 6.7. BioReliance: Overview of Service Portfolio
Figure 6.8. Merck KGaA: Annual Revenues, 2012 –2018 (USD Billion)
Figure 6.9. Merck KGaA: Annual Revenues by Business Sector, 2018 (EUR Billion)
Figure 6.10. Emergent BioSolutions: Overview of Service Portfolio
Figure 6.11. Emergent BioSolutions: Annual Revenues, 2012- 2018 (USD Million)
Figure 6.12. Emergent BioSolutions: Revenues of Contract Manufacturing Business Division, 2012-2018 (USD Million)
Figure 6.13. Patheon: Overview of Development Services Portfolio
Figure 6.14. Patheon: Overview of Development Services Portfolio
Figure 6.15. Thermo Fisher Scientific: Annual Revenues, 2012 – 2018 (USD Billion)
Figure 6.16. Patheon: Annual Revenues, 2012 – H1 2017 (USD Million)
Figure 6.17. Patheon: Revenues by Business Segments in 2016 (USD Million)
Figure 7.1. Boehringer Ingelheim BioXcellence: Overview of Service Portfolio
Figure 7.2. Boehringer Ingelheim: Annual Revenues, 2012- 2018 (EUR Billion)
Figure 7.3. IDT Biologika: Overview of Service Portfolio
Figure 7.4. Lonza: Overview of Service Portfolio
Figure 7.5. Lonza: Annual Revenues, 2012- 2018 (CHF Million)
Figure 7.6. Recipharm: Overview of Service Portfolio
Figure 7.7. Recipharm: Annual Revenues, 2012- 2018 (SEK Million)
Figure 7.8. Vetter Pharma: Overview of Service Portfolio
Figure 8.1. Biocon: Overview of Service Portfolio
Figure 8.2. Biocon: Annual Revenues, 2012-2018 (INR Billion)
Figure 8.3. Biocon: Revenues by Business Divisions, 2018 (INR Billion)
Figure 8.4. ChemPartner: Overview of Service Portfolio
Figure 8.5. LuinaBio: Overview of Service Portfolio
Figure 8.6. Mycenax Biotech: Overview of Service Portfolio
Figure 8.7. Mycenax Biotech: Annual Revenues, 2014-2018 (TWD Million)
Figure 8.8. WuXi Biologics: Overview of Service Portfolio
Figure 8.9. WuXi Biologics: Annual Revenues, 2014-2018 (RMB Million)
Figure 9.1. Partnerships and Collaborations: Distribution by Year, 2013-2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Type of Service
Figure 9.4. Partnerships and Collaborations: Distribution by Scale of Operation and Type of Service
Figure 9.5. Partnerships and Collaborations: Distribution by Type of Biologic and Type of Service
Figure 9.6. Partnerships and Collaborations: Distribution by Geographical Location
Figure 9.7. Partnerships and Collaborations: Most Active Players
Figure 9.8. Service Alliances and Supply Agreements: Distribution by Type of Service
Figure 9.9. Acquisitions and Mergers: Distribution by Type of Service
Figure 10.1. Expansions: Distribution by Year, 2013-2019
Figure 10.2. Expansions: Distribution by Type of Expansion
Figure 10.3. Expansions: Distribution by Type of Packaging
Figure 10.4. Expansions: Distribution by Type of Expansion and Type of Service
Figure 10.5. Expansions: Distribution by Type of Biologic
Figure 10.6. Expansions: Distribution by Geographical Location
Figure 10.7. Expansions: Distribution by Geography and Year, 2013-2019
Figure 10.8. Expansions: Distribution by Type of Biologic and Scale of Operation
Figure 10.9. Expansions: Most Active Players
Figure 10.10. Expansions in North America: Distribution by Type of Service and Type of Biologic
Figure 10.11. Expansions in Europe: Distribution by Type of Service and Type of Biologic
Figure 10.12. Expansions in Asia Pacific: Distribution by Type of Service and Type of Biologic
Figure 11.1. Biologics Fill / Finish Service Providers for Ampoules: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Figure 11.2. Biologics Fill / Finish Service Providers for Cartridges: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Figure 11.3. Biologics Fill / Finish Service Providers for Syringes: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Figure 11.4. Biologics Fill / Finish Service Providers for Vials: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Figure 11.5. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Type of Packaging (Million)
Figure 11.6. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Size of Manufacturer (Million)
Figure 11.7. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Scale of Operation (Million)
Figure 11.8. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Location of Headquarters (Million)
Figure 11.9. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Figure 11.10. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Type of Packaging (Liters)
Figure 11.11. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Size of Manufacturer (Liters)
Figure 11.12. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Scale of Operation (Liters)
Figure 11.13. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Location of Headquarters (Liters)
Figure 11.14. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.15. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Size of Manufacturer (Million)
Figure 11.16. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Figure 11.17. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Scale of Operation (Million)
Figure 11.18. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Location of Headquarters (Million)
Figure 11.19. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Figure 11.20. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Size of Manufacturer (Liters)
Figure 11.21. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Figure 11.22. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Scale of Operation (Liters)
Figure 11.23. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Location of Headquarters (Liters)
Figure 11.24. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.25. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Size of Manufacturer (Million)
Figure 11.26. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Figure 11.27. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Scale of Operation (Million)
Figure 11.28. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Location of Headquarters (Million)
Figure 11.29. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Figure 11.30. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Size of Manufacturer (Liters)
Figure 11.31. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Figure 11.32. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Scale of Operation (Liters)
Figure 11.33. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Location of Headquarters (Liters)
Figure 11.34. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.35. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Size of Manufacturer (Million)
Figure 11.36. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Figure 11.37. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Scale of Operation (Million)
Figure 11.38. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Location of Headquarters (Million)
Figure 11.39. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Figure 11.40. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Size of Manufacturer (Liters)
Figure 11.41. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Figure 11.42. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Scale of Operation (Liters)
Figure 11.43. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Location of Headquarters (Liters)
Figure 11.44. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.45. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Size of Manufacturer (Million)
Figure 11.46. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Figure 11.47. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Scale of Operation (Million)
Figure 11.48. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Location of Headquarters (Million)
Figure 11.49. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Figure 11.50. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Size of Manufacturer (Liters)
Figure 11.51. Global Biologics Fill / Finish Capacity for Vials (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Figure 11.52. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Scale of Operation (Liters)
Figure 11.53. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Location of Headquarters (Liters)
Figure 11.54. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Figure 11.55. Biologics Fill / Finish Service Providers: Distribution of Global Capacity by Location of Fill / Finish Facilities
Figure 11.56. Biologics Fill / Finish Service Providers: Distribution of Global Capacity by Packaging Form and Size of Service Provider
Figure 12.1. Global Demand for Biologics Fill / Finish Services
Figure 12.2. Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging
Figure 12.3. Global Demand for Biologics Fill / Finish Services: Distribution by Scale of Operation
Figure 12.4. Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic
Figure 12.5. Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area
Figure 12.6. Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location
Figure 12.7. Global Biologics Fill / Finish Services: Demand and Supply
Figure 13.1. Biologics Fill / Finish Service Providers: Key Performance Indicators (KPIs)
Figure 13.2. Financial Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.3. Financial Indicators: Big Pharma Perspective
Figure 13.4. Financial Indicators: Contract Manufacturers’ Perspective
Figure 13.5. Process / Capability Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.6. Process / Capability Indicators: Big Pharma Perspective
Figure 13.7. Process / Capability Indicators: Contract Manufacturers’ Perspective
Figure 13.8. Market Reputation Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.9. Market Reputation Indicators: Big Pharma Perspective
Figure 13.10. Market Reputation Indicators: Contract Manufacturers’ Perspective
Figure 14.1. Overall Biologics Fill / Finish Services Market, 2019-2030 (USD Billion)
Figure 14.2. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Packaging (USD Billion)
Figure 14.3. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Scale of Operation (USD Billion)
Figure 14.4. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Biologic (USD Billion)
Figure 14.5. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Therapeutic Area (USD Billion)
Figure 14.6. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Geographical Region (USD Billion)
Figure 14.7. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Packaging (USD Billion)
Figure 14.8. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Scale of Operation (USD Billion)
Figure 14.9. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Biologic (USD Billion)
Figure 14.10. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Therapeutic Area (USD Billion)
Figure 14.11. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Packaging (USD Billion)
Figure 14.12. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Scale of Operation (USD Billion)
Figure 14.13. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Biologic (USD Billion)
Figure 14.14. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Therapeutic Area (USD Billion)
Figure 14.15. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Packaging (USD Billion)
Figure 14.16. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Scale of Operation (USD Billion)
Figure 14.17. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Biologic (USD Billion)
Figure 14.18. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Therapeutic Area (USD Billion)
Figure 14.19. Biologics Fill / Finish Services Market for Ampoules, 2019-2030 (USD Million)
Figure 14.20. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.21. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.22. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.23. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Geographical Region (USD Million)
Figure 14.24. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.25. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.26. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.27. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.28. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.29. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.30. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.31. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.32. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.33. Biologics Fill / Finish Services Market for Cartridges, 2019-2030 (USD Million)
Figure 14.34. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.35. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.36. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.37. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Geographical Region (USD Million)
Figure 14.38. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.39. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.40. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.41. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.42. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.43. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.44. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.45. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.46. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.47. Biologics Fill / Finish Services Market for Syringes, 2019-2030 (USD Million)
Figure 14.48. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.49. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.50. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.51. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Geographical Region (USD Million)
Figure 14.52. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.53. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.54. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.55. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.56. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.57. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.58. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.59. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.60. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.61. Biologics Fill / Finish Services Market for Vials, 2019-2030 (USD Million)
Figure 14.62. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.63. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.64. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.65. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Geographical Region (USD Million)
Figure 14.66. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.67. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.68. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.69. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.70. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.71. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 14.72. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Scale of Operation (USD Million)
Figure 14.73. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Type of Biologic (USD Million)
Figure 14.74. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Therapeutic Area (USD Million)
Figure 15.1. Growth Opportunities for Biologics Fill / Finish Service Providers
Figure 15.2. New Molecular Entities Approved by the FDA, 2011-2018
Figure 16.1. Key Considerations for Selecting a Robotic System
Figure 16.2. Advantages of Robotic Systems in Pharmaceutical Operations
Figure 17.1. Drivers of Ready-to-Use Platform
Figure 18.1. Overall Biologics Fill / Finish Services Market, 2020, 2025 and 2030: Conservative, Base and Optimistic Scenarios

List of Tables

Table 3.1. Best-Selling Drugs of 2018
Table 4.1. Biologics Fill / Finish Service Providers: List of Companies
Table 4.2. Biologics Fill / Finish Service Providers: Information on Type of Packaging
Table 4.3. Biologics Fill / Finish Service Providers: Information on Additional Services Offered
Table 4.4. Biologics Fill / Finish Service Providers: Information on Scale of Operation
Table 4.5. Biologics Fill / Finish Service Providers: Information on Type of Biologic
Table 4.6. Biologics Fill / Finish Service Providers: Information on Fill / Finish Capability
Table 6.1. Biologics Fill / Finish Service Providers in North America: List of Profiled Companies
Table 6.2. ABL: Company Overview
Table 6.3. ABL: Overview of Drug Product Solutions
Table 6.4. ABL: Sterile Manufacturing Facilities
Table 6.5. ABL: Future Outlook
Table 6.6. AMRI: Company Overview
Table 6.7. AMRI: Overview of Drug Product Solutions
Table 6.8. AMRI: Sterile Manufacturing Facilities
Table 6.9. AMRI: Future Outlook
Table 6.10. BioPharma Solutions: Company Overview
Table 6.11. BioPharma Solutions: Overview of Drug Product Solutions
Table 6.12. BioPharma Solutions: Sterile Manufacturing Facilities
Table 6.13. BioPharma Solutions: Future Outlook
Table 6.14. BioReliance: Company Overview
Table 6.15. BioReliance: Overview of Drug Product Solutions
Table 6.16. BioReliance: Sterile Manufacturing Facilities
Table 6.17. BioReliance (MilliporeSigma): Future Outlook
Table 6.18. Emergent BioSolutions: Company Overview
Table 6.19. Emergent BioSolutions: Overview of Drug Product Solutions
Table 6.20. Emergent BioSolutions: Sterile Manufacturing Facilities
Table 6.21. Emergent BioSolutions: Future Outlook
Table 6.22. Patheon: Company Overview
Table 6.23. Patheon: Overview of Drug Product Solutions
Table 6.24. Patheon: Sterile Manufacturing Facilities
Table 6.25. Patheon: Future Outlook
Table 7.1. Biologics Fill / Finish Service Providers in Europe: List of Profiled Companies
Table 7.2. Boehringer Ingelheim BioXcellence: Company Overview
Table 7.3. Boehringer Ingelheim BioXcellence: Overview of Drug Product Solutions
Table 7.4. Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 7.5. Boehringer Ingelheim BioXcellence: Future Outlook
Table 7.6. IDT Biologika: Company Overview
Table 7.7. IDT Biologika: Overview of Drug Product Solutions
Table 7.8. IDT Biologika: Future Outlook
Table 7.9. Lonza: Company Overview
Table 7.10. Lonza: Overview of Drug Product Solutions
Table 7.11. Lonza: Future Outlook
Table 7.12. Recipharm: Company Overview
Table 7.13. Recipharm: Overview of Drug Product Solutions
Table 7.14. Recipharm: Sterile Manufacturing Facilities
Table 7.15. Recipharm: Future Outlook
Table 7.16. Vetter Pharma: Company Overview
Table 7.17. Vetter Pharma: Overview of Drug Product Solutions
Table 7.18. Vetter Pharma: Future Outlook
Table 8.1. Biologics Fill / Finish Service Providers in Asia-Pacific: List of Profiled Companies
Table 8.2. Biocon: Company Overview
Table 8.3. Biocon: Overview of Drug Product Solutions
Table 8.4. Biocon: Future Outlook
Table 8.5. ChemPartner: Company Overview
Table 8.6. ChemPartner: Overview of Drug Product Solutions
Table 8.7. ChemPartner: Future Outlook
Table 8.8. LuinaBio: Company Overview
Table 8.9. LuinaBio: Overview of Drug Product Solutions
Table 8.10. LuinaBio: Future Outlook
Table 8.11. Mycenax Biotech: Company Overview
Table 8.12. Mycenax Biotech: Overview of Drug Product Solutions
Table 8.13. Mycenax Biotech: Future Outlook
Table 8.14. WuXi Biologics: Company Overview
Table 8.15. WuXi Biologics: Overview of Drug Product Solutions
Table 8.16. WuXi Biologics: Sterile Manufacturing Facilities
Table 8.17. WuXi Biologics: Future Outlook
Table 9.1. Biologics Fill / Finish Service Providers: Partnerships and Collaborations, 2013-2019
Table 9.2. Partnerships and Collaborations: Information on Types of Biologics, 2013-2019
Table 9.3. Service Alliances and Supply Agreements: Information on Types of Services
Table 9.4. Acquisitions and Mergers: Information on Types of Services
Table 10.1. Biologics Fill / Finish Service Providers: Recent Expansions, 2013-2019
Table 10.2. Expansions: Information on Types of Packaging
Table 10.3. Expansions: Information on Types of Services
Table 10.4. Expansions: Information on Types of Biologics
Table 11.1. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Average Capacity by Size of Manufacturer (Sample Data Set)
Table 11.2. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Average Capacity by Size of Manufacturer (Sample Data Set)
Table 11.3. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Average Capacity by Size of Manufacturer (Sample Data Set)
Table 11.4. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Average Capacity by Size of Manufacturer (Sample Data Set)
Table 11.5. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Size of Manufacturer
Table 11.6. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Size of Manufacturer
Table 11.7. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Size of Manufacturer
Table 11.8. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Size of Manufacturer
Table 15.1. Patent Expiry of Biologics, 2018-2023
Table 16.1. Biologics Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
Table 16.2. List of Pharmaceutical Robotics Manufacturers
Table 17.1. List of Companies Supplying Ready-to-Use Packaging Components
Table 20.1. Biologics Fill / Finish Service Providers: Analysis by Year of Establishment
Table 20.2. Biologics Fill / Finish Service Providers: Analysis by Company Size
Table 20.3. Biologics Fill / Finish Service Providers: Analysis by Location of Headquarters
Table 20.4. Biologics Fill / Finish Service Providers: Analysis by Location of Fill / Finish Facilities
Table 20.5. Biologics Fill / Finish Service Providers: Analysis by Type of Packaging
Table 20.6. Biologics Fill / Finish Service Providers: Analysis by Type of Additional Services Offered
Table 20.7. Biologics Fill / Finish Service Providers: Analysis by Scale of Operation
Table 20.8. Biologics Fill / Finish Service Providers: Analysis by Type of Biologic
Table 20.9. AMRI: Annual Revenues, 2012- Q1 2017 (USD Million)
Table 20.10. AMRI: Revenues by Business Divisions, 2016 (USD Million)
Table 20.11. Baxter International: Annual Revenues, 2012 –2018 (USD Billion)
Table 20.12. Merck KGaA: Annual Revenues, 2012 –2018 (USD Billion)
Table 20.13. Merck KGaA: Annual Revenues by Business Sector, 2018 (EUR Billion)
Table 20.14. Emergent BioSolutions: Annual Revenues, 2012- 2018 (USD Million)
Table 20.15. Emergent BioSolutions: Revenues of Contract Manufacturing Business Division, 2012-2018 (USD Million)
Table 20.16. Thermo Fisher Scientific: Annual Revenues, 2012 – 2018 (USD Billion)
Table 20.17. Patheon: Annual Revenues, 2012 – H1 2017 (USD Million)
Table 20.18. Patheon: Revenues by Business Segments in 2016 (USD Million)
Table 20.19. Boehringer Ingelheim: Annual Revenues, 2012- 2018 (EUR Billion)
Table 20.20. Lonza: Annual Revenues, 2012- 2018 (CHF Million)
Table 20.21. Recipharm: Annual Revenues, 2012- 2018 (SEK Million)
Table 20.22. Biocon: Annual Revenues, 2012-2018 (INR Billion)
Table 20.23. Biocon: Revenues by Business Divisions, 2018 (INR Billion)
Table 20.24. Mycenax Biotech: Annual Revenues, 2014-2018 (TWD Million)
Table 20.25. WuXi Biologics: Annual Revenues, 2014-2018 (RMB Million)
Table 20.26. Partnerships and Collaborations: Distribution by Year, 2013-2019
Table 20.27. Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.28. Partnerships and Collaborations: Distribution by Type of Service
Table 20.29. Partnerships and Collaborations: Distribution by Scale of Operation and Type of Service
Table 20.30. Partnerships and Collaborations: Distribution by Type of Biologic and Type of Service
Table 20.31. Partnerships and Collaborations: Distribution by Geographical Location
Table 20.32. Partnerships and Collaborations: Most Active Players
Table 20.33. Service Alliances and Supply Agreements: Distribution by Types of Service
Table 20.34. Acquisitions and Mergers: Distribution by Types of Service
Table 20.35. Expansions: Distribution by Year, 2013-2019
Table 20.36. Expansions: Distribution by Type of Expansion
Table 20.37. Expansions: Distribution by Type of Packaging
Table 20.38. Expansions: Distribution by Type of Expansion and Type of Service
Table 20.39. Expansions: Distribution by Type of Biologic
Table 20.40. Expansions: Distribution by Geographical Location
Table 20.41. Expansions: Distribution by Type of Biologic and Scale of Operation
Table 20.42. Expansions: Most Active Players
Table 20.43. Expansions in North America: Distribution by Type of Service and Type of Biologic
Table 20.44. Expansions in Europe: Distribution by Type of Service and Type of Biologic
Table 20.45. Expansions in Asia Pacific: Distribution by Type of Service and Type of Biologic
Table 20.46. Biologics Fill / Finish Service Providers for Ampoules: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Table 20.47. Biologics Fill / Finish Service Providers for Cartridges: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Table 20.48. Biologics Fill / Finish Service Providers for Syringes: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Table 20.49. Biologics Fill / Finish Service Providers for Vials: Distribution of Capacity by Size of Manufacturer (Sample Data Set)
Table 20.50. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Type of Packaging (Million)
Table 20.51. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Size of Manufacturer (Million)
Table 20.52. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Scale of Operation (Million)
Table 20.53. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Location of Headquarters (Million)
Table 20.54. Global Biologics Fill / Finish Capacity (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Table 20.55. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Type of Packaging (Liters)
Table 20.56. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Size of Manufacturer (Liters)
Table 20.57. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Scale of Operation (Liters)
Table 20.58. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Location of Headquarters (Liters)
Table 20.59. Global Biologics Fill / Finish Capacity (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 20.60. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Size of Manufacturer (Million)
Table 20.61. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Table 20.62. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Scale of Operation (Million)
Table 20.63. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Location of Headquarters (Million)
Table 20.64. Global Biologics Fill / Finish Capacity for Ampoules (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Table 20.65. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Size of Manufacturer (Liters)
Table 20.66. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Table 20.67. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Scale of Operation (Liters)
Table 20.68. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Location of Headquarters (Liters)
Table 20.69. Global Biologics Fill / Finish Capacity for Ampoules (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 20.70. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Size of Manufacturer (Million)
Table 20.71. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Table 20.72. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Scale of Operation (Million)
Table 20.73. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Location of Headquarters (Million)
Table 20.74. Global Biologics Fill / Finish Capacity for Cartridges (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Table 20.75. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Size of Manufacturer (Liters)
Table 20.76. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Table 20.77. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Scale of Operation (Liters)
Table 20.78. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Location of Headquarters (Liters)
Table 20.79. Global Biologics Fill / Finish Capacity for Cartridges (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 20.80. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Size of Manufacturer (Million)
Table 20.81. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Table 20.82. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Scale of Operation (Million)
Table 20.83. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Location of Headquarters (Million)
Table 20.84. Global Biologics Fill / Finish Capacity for Syringes (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Table 20.85. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Size of Manufacturer (Liters)
Table 20.86. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Table 20.87. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Scale of Operation (Liters)
Table 20.88. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Location of Headquarters (Liters)
Table 20.89. Global Biologics Fill / Finish Capacity for Syringes (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 20.90. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Size of Manufacturer (Million)
Table 20.91. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Range of Capacity by Size of Manufacturer (Million)
Table 20.92. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Scale of Operation (Million)
Table 20.93. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Location of Headquarters (Million)
Table 20.94. Global Biologics Fill / Finish Capacity for Vials (by Number of Units): Distribution by Location of Fill / Finish Facilities (Million)
Table 20.95. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Size of Manufacturer (Liters)
Table 20.96. Global Biologics Fill / Finish Capacity for Vials (by Volume): Range of Capacity by Size of Manufacturer (Liters)
Table 20.97. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Scale of Operation (Liters)
Table 20.98. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Location of Headquarters (Liters)
Table 20.99. Global Biologics Fill / Finish Capacity for Vials (by Volume): Distribution by Location of Fill / Finish Facilities (Liters)
Table 20.100. Biologics Fill / Finish Service Providers: Distribution of Global Capacity by Location of Fill / Finish Facilities
Table 20.101. Biologics Fill / Finish Service Providers: Distribution of Global Capacity by Packaging Form and Size of Service Provider
Table 20.102. Global Demand for Biologics Fill / Finish Services
Table 20.103. Global Demand for Biologics Fill / Finish Services: Distribution by Type of Packaging
Table 20.104. Global Demand for Biologics Fill / Finish Services: Distribution by Scale of Operation
Table 20.105. Global Demand for Biologics Fill / Finish Services: Distribution by Type of Biologic
Table 20.106. Global Demand for Biologics Fill / Finish Services: Distribution by Therapeutic Area
Table 20.107. Global Demand for Biologics Fill / Finish Services: Distribution by Geographical Location
Table 20.108. Overall Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Packaging, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.109. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.110. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.111. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.112. Biologics Fill / Finish Services Market, 2019-2030: Distribution by Geographical Region, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.113. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Packaging, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.114. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.115. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.116. Biologics Fill / Finish Services Market in North America, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.117. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Packaging, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.118. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.119. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.120. Biologics Fill / Finish Services Market in Europe, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.121. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Packaging, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.122. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.123. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.124. Biologics Fill / Finish Services Market in Asia Pacific, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 20.125. Biologics Fill / Finish Services Market for Ampoules, 2019-2030 (USD Million): Conservative, Base and Optimistic Scenarios
Table 20.126. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.127. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.128. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.129. Biologics Fill / Finish Services Market for Ampoules, 2019-2030: Distribution by Geographical Region, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.130. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.131. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.132. Biologics Fill / Finish Services Market for Ampoules in North America, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.133. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.134. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.135. Biologics Fill / Finish Services Market for Ampoules in Europe, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.136. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.137. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.138. Biologics Fill / Finish Services Market for Ampoules in Asia Pacific, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.139. Biologics Fill / Finish Services Market for Cartridges, 2019-2030 (USD Million): Conservative, Base and Optimistic Scenarios
Table 20.140. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.141. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.142. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.143. Biologics Fill / Finish Services Market for Cartridges, 2019-2030: Distribution by Geographical Region, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.144. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.145. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.146. Biologics Fill / Finish Services Market for Cartridges in North America, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.147. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.148. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.149. Biologics Fill / Finish Services Market for Cartridges in Europe, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.150. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.151. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.152. Biologics Fill / Finish Services Market for Cartridges in Asia Pacific, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.153. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.154. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.155. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.156. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.157. Biologics Fill / Finish Services Market for Syringes, 2019-2030: Distribution by Geographical Region, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.158. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.159. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.160. Biologics Fill / Finish Services Market for Syringes in North America, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.161. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.162. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.163. Biologics Fill / Finish Services Market for Syringes in Europe, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.164. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.165. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.166. Biologics Fill / Finish Services Market for Syringes in Asia Pacific, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.167. Biologics Fill / Finish Services Market for Vials, 2019-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.168. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.169. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.170. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.171. Biologics Fill / Finish Services Market for Vials, 2019-2030: Distribution by Geographical Region, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.172. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.173. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.174. Biologics Fill / Finish Services Market for Vials in North America, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.175. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.176. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.177. Biologics Fill / Finish Services Market for Vials in Europe, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.178. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.179. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Type of Biologic, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.180. Biologics Fill / Finish Services Market for Vials in Asia Pacific, 2019-2030: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios (USD Million)
Table 20.181. Overall Biologics Fill / Finish Services Market, 2020, 2025 and 2030: Conservative, Base and Optimistic Scenarios

List of Companies

The following companies and organizations have been mentioned in the report.

  1. AbbVie
  2. Adimmune 
  3. Advanced BioScience Laboratories
  4. Afton Scientific 
  5. Agilis Biotherapeutics
  6. Ajinomoto Bio-Pharma Services
  7. Akron Biotech
  8. Alcami
  9. Alcon
  10. Allergy Laboratories
  11. Amatsigroup
  12. Amgen
  13. Amicus Therapeutics 
  14. AMRI 
  15. Anchiano Therapeutics
  16. apceth Biopharma
  17. APG Europe
  18. Aptar Pharma
  19. Aptuit
  20. Arabio
  21. ARaymond Life
  22. Arch Biopartners
  23. Aseptic Technologies 
  24. Austrianova
  25. Axcellerate Pharma
  26. Baccinex 
  27. Bausch & Ströbel 
  28. BAUSCH Advanced Technology Group
  29. Bayer
  30. Baxter
  31. Becton Dickinson
  32. Bio Elpida
  33. Biocon
  34. Bio-Concept Laboratories
  35. BioConnection
  36. Biofabri 
  37. Biogen
  38. BioMARC
  39. Biomedical Advanced Research and Development Authority 
  40. BioPharma Solutions
  41. BioReliance
  42. BioTechLogic
  43. BioTechnique
  44. Biotechpharma
  45. Biovian
  46. Boehringer Ingelheim BioXcellence
  47. Bosch Packaging Technology
  48. Brammer Bio
  49. Bristol-Myers Squibb
  50. Bryllan
  51. Burrard Pharmaceuticals
  52. Canada Peptide
  53. Cangene
  54. Capmatic
  55. CARBOGEN AMCIS
  56. Catalent Biologics
  57. Celgene
  58. Cell Culture Company 
  59. Cellin Technologies
  60. Celonic
  61. Cenexi
  62. Cerbios-Pharma
  63. Cerium Pharmaceuticals
  64. Chase-Logeman
  65. China Gateway Biologics
  66. CinnaGen
  67. CMC Biologics
  68. Cobra Biologics
  69. Coldstream Laboratories
  70. Cook Pharmica
  71. CordenPharma
  72. Cozzoli Machine Company
  73. Cytovance Biologics
  74. Daikyo Seiko
  75. Dalton Pharma Services
  76. Datwyler Group
  77. DM Bio
  78. Dr. Reddy's Custom Pharma Services
  79. DSM Pharmaceutical Products
  80. DWK Life Sciences
  81. EirGen Pharma
  82. EMA Pharmaceuticals
  83. Emergent BioSolutions
  84. EuBiologics
  85. EUCODIS Bioscience
  86. Eurofins Scientific
  87. EVER Pharma
  88. Exelead
  89. Fresenius Kabi Contract Manufacturing
  90. FUJIFILM Diosynth Biotechnologies
  91. Gadea Pharmaceutical (acquired by AMRI)
  92. Genentech
  93. Generic Specialities
  94. GenIbet Biopharmaceuticals
  95. Gerresheimer
  96. GlaxoSmithKline 
  97. GLyPharma (acquired by Therachon)
  98. Goodwin Biotechnology
  99. Grand River Aseptic Manufacturing
  100. Gröninger 
  101. GTCR
  102. HALIX
  103. hameln Pharmaceuticals
  104. Health Biotech
  105. Hepalink USA
  106. Hisun Pharmaceuticals USA
  107. Hitachi Chemical Advanced Therapeutics Solutions
  108. HOOKIPA Pharma
  109. Hycult Biotech
  110. IDT Biologika
  111. IMA Group
  112. Immune Pharmaceuticals
  113. Infectious Disease Research Institute
  114. Intas Pharmaceuticals
  115. Integrity Bio
  116. JHL Biotech
  117. Johnson & Johnson
  118. Jubilant HollisterStier
  119. KABS Pharmaceutical Services
  120. Kaysersberg Pharmaceuticals (acquired by Recipharm)
  121. Kemwell Biopharma
  122. Kyowa Hakko Kirin
  123. Lonza
  124. LSNE Contract Manufacturing
  125. LuinaBio
  126. Lyophilization Technology
  127. M&O Perry
  128. MabPlex
  129. Madison Dearborn Partners
  130. MassBiologics
  131. Merck
  132. Microdermics 
  133. Millmount Healthcare (acquired by PCI Services)
  134. Miltenyi Biotec
  135. Morgridge Institute for Research
  136. Mycenax Biotech
  137. Najít Technologies
  138. National Institutes of Health
  139. Ningbo Zhengli Pharmaceutical Packing
  140. Nipro PharmaPackaging
  141. Nitto Avecia Pharma Services
  142. Nitto Denko Avecia
  143. Nova Laboratories
  144. Novartis
  145. Novasep
  146. Ompi
  147. oncomed manufacturing
  148. Oncotec Pharma Produktion
  149. OPKO Health
  150. OPTIMA pharma
  151. Oryn Therapeutics
  152. Oso BioPharmaceutical Manufacturing 
  153. Ottawa Hospital Research Institute
  154. Pall Life Sciences
  155. Panacea Pharmaceuticals
  156. Paragon Bioservices
  157. Partners Group
  158. Patheon
  159. PCI Pharma Services 
  160. PCT
  161. Penn Pharmaceutical Services
  162. Permira 
  163. Pfizer
  164. Pharmaceutical Packaging Professionals
  165. Pierre Fabre
  166. Piramal Pharma Solutions
  167. Polpharma Biologics
  168. Polymun Scientific
  169. Praxis Pharmaceutical
  170. PrimaPharma
  171. Prince Sterilization Services
  172. PSC Biotech
  173. PYRAMID Laboratories
  174. Quality BioResources
  175. Recipharm
  176. Regeneron Pharmaceuticals
  177. Reliance Life Sciences
  178. Rentschler Biotechnologie
  179. Rentschler Fill Solutions
  180. Roche 
  181. Rommelag CMO
  182. RoslinCT
  183. ROTA Verpackungstechnik
  184. SAFC
  185. Samsung Bioepis
  186. Samsung BioLogics
  187. Sanofi
  188. Saudi Biotechnology Manufacturing
  189. SCHOTT 
  190. Selecta Biosciences
  191. Shenzhen Hepalink Pharmaceutical
  192. Sherpa Clinical Packaging (acquired by PCI Pharma Services)
  193. SialoCarb
  194. Siegfried Holding
  195. Singota Solutions
  196. SiO2 Medical Products
  197. SIRION Biotech 
  198. SME Biotech Consulting
  199. Stevanato Group
  200. Swissfillon 
  201. Symbiosis Pharmaceutical Services
  202. Symphogen
  203. Syngene
  204. Sypharma
  205. Tanvex BioPharma
  206. The Carlyle Group 
  207. Therapure Biomanufacturing
  208. Thermo Fisher Scientific
  209. Transcoject
  210. Ultragenyx Pharmaceutical
  211. Vanrx Pharmasystems
  212. Vetter Pharma
  213. VGXI
  214. Vibalogics
  215. Vigene Biosciences
  216. Waisman Biomanufacturing
  217. Watson-Marlow Fluid Technology Group
  218. West Pharmaceutical Services
  219. WuXi Biologics
  220. Wuxi Fortune Pharmaceutical
  221. Wuxi Griffin Pharmaceuticals
  222. Yposkesi

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com